The potential to disrupt the market...For the newcomers on this board, here is one more reason to hold on to your TLT shares.
In this link...
Latest data from bladder cancer study to propel future growth | 2024-10-10 | Investing News | Stockhouse Note: The Market Online is sponsored(Paid advertising)
But still there is an interesting quote under '' Addressing an unmet medical need''
Last paragraph...
It said ''
Theralase has the potential to disrupt the market''. Question?
How can TLT disrupt the market???
The answer could be in this link...
C:\Users\MPERRA~1\AppData\Local\Temp\mso7A8C.tmp It said''
Theralase is safer and more effective than all currently FDA approved drugs''( for BCG resistant patients).
TLT-Ruvidar=
34%CR at 450 days. Keytruda = 18.9% at 450 days.
Adstiladrin= 23.5% at 450 days(Adstiladrin can't treat immune-deficient patients).
ImmunityBio Anktiva 36%CR at 360 days(ImmunityBio anktiva is a 37 months long maintenance therapy that doesn't even cure the cancer).
-Merck keytruda, ImmunityBio Anktiva & Adstiladrin are all
continuous treatments, you have to take these treatments for as long as you can tolerate them, or until you develop resistance.
NOTE: Merck & ImmunityBio with there huge budget(Merck billion $), could not come up with a decent '' One And Done Treatment'' for BCG resistant patients.
That says it all about TLT achievements on a shoestring budget. BTD approval...
Keytruda did get the FDA BTD approval(2013).
Adstiladrin did get the FDA BTD approval.
ImmunityBio Anktiva did get the FDA BTD approval.
-With a treatment(Ruvidar) safer and more effective than all the above FDA approved drugs for BCG resistant patients, it's easy to conclude that TLT-Ruvidar is next in line for the FDA BTD approval.
Unmet Medical Need.
Al the above indicate that there is an '' Unmet Medical Need'' for these patients.
In short...
The FDA badly need a '' One And Done Treatment''(TLT-Ruvidar), that has the best CR% in the business, can treat 100% of patients without restrictions, is 100% safe, and can treat heavily pretreated patients.
Worth repeating...
Theralase has the potential to disrupt the market. And Bladder cancer is just the first step, other cancer are coming.
How much$ is worth a treatment that can disrupt the market???
Answer '' A Ton Of Money''.
I love my TLT shares.
.